Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 4
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 4(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04641819Phase 4Unknown

Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients

Role: collaborator

NCT04408261Phase 2Unknown

BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

Role: collaborator

NCT02280850Phase 4Unknown

Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina

Role: lead

All 3 trials loaded